NanoMed Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
The idea of delivering drugs encased in lipids was a popular one in the early days of the biotechnology industry but manufacturing problems pushed lipid-based drug delivery from favor. NanoMed Pharmaceuticals thinks it has found a way to get lipids to fulfill their potential as delivery vehicles, shielding the drugs they contain from cellular mechanisms responsible for drug resistance. The start-up aims to leverage its know-how to treat cancers notoriously resistant to chemotherapy.